Q-omics provides the consensus-scored GYG1P3 profile across patient tissues and cancer cell-line models. GYG1P3 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in THYM. Among the 18 cancer types available for tumor–normal comparison, GYG1P3 is differentially expressed in 5, with the highest sampling consensus in KIRP. Additionally, GYG1P3 RNA expression shows 6,514 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight THYM, KIRP, and STAD as cancer lineages where GYG1P3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GYG1P3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GYG1P3 survival associations across molecular data types. GYG1P3 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GYG1P3 RNA expression–survival associations across cancer types. High GYG1P3 expression shows unfavorable associations in THYM, MESO, READ, ACC and DLBC, but favorable associations in KIRC. The THYM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .004). Together, the overview and detailed table identify THYM as the clearest survival context for GYG1P3 RNA expression.
This table summarizes GYG1P3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for GYG1P3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GYG1P3 shows lower tumor expression in LUSC, READ, ESCA and LIHC and higher tumor expression in KIRP. The KIRP box plot shows higher GYG1P3 RNA expression in tumor versus normal tissue (log2 FC = +0.054, t-test p = .003).
This table shows molecular features associated with GYG1P3 in patient tissues and cancer cell lines. In patient samples, GYG1P3 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
